40 articles found
Usona Institute has completed a new drug application for psilocybin in major depressive disorder, Psychedelic Alpha reported, as Compass Pathways races to file its own.
UC Berkeley, UCSF and Stanford labs ran identical psilocybin experiments in mice and found the drug's lasting behavioral effects did not hold up across sites.
Rep. Steve Cohen introduced a six-title rewrite of the Controlled Substances Act that shifts scheduling to HHS, eases research rules and ends mandatory minimums.
ICER will assess the clinical and economic value of Compass Pathways' synthetic psilocybin for treatment-resistant depression, with public comment open until Nov. 10.
Gabon's cabinet adopted a draft decree banning export of iboga and its derivatives, as U.S. interest in ibogaine as an addiction treatment drives demand.
The Brain & Behavior Research Foundation awarded 180 Young Investigator grants worth over $12.5 million, with half of the projects focused on depression or schizophrenia.
The FDA is taking public comment through Nov. 20 on how the first federally funded ibogaine trials should handle dosing, cardiac monitoring and safety.
Psyence BioMed's Texas unit partnered with DEA-registered Benuvia to plan U.S. manufacturing of pharmaceutical-grade ibogaine, a drug studied for opioid use disorder.
Governor Newsom signed AB 113, allocating $4.7 million for California's first state-funded research into psychedelic therapy for veterans with treatment-resistant PTSD.
A Roanoke research team wins federal funding to test whether psilocybin-assisted therapy can treat cocaine use disorder, for which no FDA-approved medication exists.
A real-world study of Oregon's regulated psilocybin program demonstrates encouraging outcomes for depression and anxiety, offering valuable data as FDA considers approval for psychedelic therapy.
Johns Hopkins University launches the nation's first clinic specifically treating rare but serious long-term side effects from psychedelic use, including hallucinogen persisting perception disorder.
Texas begins first state-funded Phase 1 clinical trials of ibogaine for opioid use disorder, PTSD, and traumatic brain injuries with additional legislative funding.
FDA sets a September 14 public hearing on therapeutic psychedelics and finalizes its first clinical trial guidance for psilocybin, LSD and MDMA.
FDA cracks down on illegal online ketamine market with 14 warning letters to websites selling non-approved ketamine products for depression and addiction treatment.
Compass Pathways' COMP360 psilocybin therapy could receive FDA approval by late 2026, marking a historic milestone for psychedelic medicine and offering new hope for treatment-resistant depression.
Republican Representative Jaime Green proposes using Michigan's opioid settlement dollars to fund clinical trials of ibogaine, a psychedelic compound showing promise for treating PTSD and addiction in veterans.
The Department of Veterans Affairs begins first government-sponsored study of MDMA-assisted therapy, enrolling 80 veterans in groundbreaking research on psychedelic treatment for co-occurring conditions.
FDA grants Breakthrough Therapy designation to LSD d-tartrate for generalized anxiety disorder, accelerating development of the first LSD-based psychiatric treatment and signaling regulatory openness to psychedelic therapies.
Stanford-led research shows low-dose buprenorphine after ketamine infusion extends anti-suicidal benefits from days to weeks, offering new hope for high-risk patients.
Louisiana legislature moves to authorize state-funded research into ibogaine, psilocybin, and MDMA for treating substance use disorders and PTSD, joining growing national movement.
Ohio's Ibogaine Treatment Study Committee convenes to explore clinical trials for ibogaine-assisted therapy, spurred by Trump's executive order accelerating psychedelic research and veteran advocacy.
University of California Davis scientists create new amino acid-based compounds that activate serotonin receptors for mental health benefits without causing hallucinations, potentially revolutionizing addiction and depression therapy.
Minnesota lawmakers vote 114-15 to legalize regulated psilocybin-assisted therapy, making the state the fourth in the nation to authorize supervised psychedelic treatment for mental health and substance use disorders.
University of Alabama at Birmingham study published in JAMA Network Open finds psilocybin-assisted therapy significantly improved abstinence rates among individuals with cocaine use disorder, offering hope for a condition with no FDA-approved medications.
FDA awards priority review vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics for psilocybin and methylone therapies targeting treatment-resistant depression and PTSD.
State Senator Pat McMath proposes using unspent opioid settlement dollars to fund clinical research into psychedelic-assisted therapy for veterans, first responders, and people with opioid dependence.
President Trump signs executive order directing FDA to fast-track psychedelic research, provides $50 million for ibogaine studies, and opens Right to Try pathway for patients with treatment-resistant mental illness.
Food and Drug Administration issues complete response letter rejecting Lykos Therapeutics' MDMA-assisted therapy for PTSD, demanding additional clinical trials despite promising efficacy data.
Intravenous DMT reduced depressive symptoms within a week in Phase IIa trial, with effects lasting up to three months, according to study published in Nature Medicine.
Mississippi, Tennessee, Texas, West Virginia, Oklahoma, and Missouri are coordinating clinical trials of ibogaine—a Schedule I psychedelic—for opioid addiction and PTSD despite federal restrictions.
Kentucky Senate Bill 77 nears final passage, creating framework to research ibogaine for opioid addiction and PTSD despite Schedule I status. Four states already funding trials.
Oregon and Colorado lead regulated psilocybin therapy programs as research shows promise for depression, PTSD, and addiction. Personal stories reveal profound results.
New Nature Mental Health study finds combining low-dose ketamine with mindfulness training improves outcomes for people receiving buprenorphine treatment, opening door to psychedelic-assisted interventions
University of Arizona trial finds 73% of participants responded to multiple psilocybin sessions, with 40% achieving remission from obsessive-compulsive disorder symptoms lasting six months.
Minnesota lawmakers approved HF 2906, creating a state-regulated psilocybin therapy pilot program with patient caps and bipartisan backing, joining Oregon and Colorado.
Mississippi Senate passes HB 314, allocating $5M from opioid settlement funds to join Texas and Arizona in FDA clinical trials of ibogaine for opioid addiction and PTSD treatment.
New research identifies myelin remodeling as the missing link between short-term psychedelic experiences and long-term PTSD relief, shifting focus from neurons to oligodendrocytes.
Missouri's Veterans Mental Health Innovation Act would fund FDA ibogaine clinical trials for opioid use disorder and traumatic brain injury, joining Texas and Arizona in breakthrough therapy research.
Imperial College London study published in Nature finds that a single 30-minute DMT session with therapeutic support reduced depressive symptoms more effectively than placebo, marking another step forward for psychedelic-assisted mental health treatment.